TipRanks
Advertisement
Advertisement

CGTX Stock Latest News

Cognition Therapeutics: Patent Extension and Pivotal CNS Catalysts Support Buy Rating with Unchanged $3 Price Target
RatingsCognition Therapeutics: Patent Extension and Pivotal CNS Catalysts Support Buy Rating with Unchanged $3 Price Target
5d ago
CGTX
Cognition Therapeutics issued patent covering novel crystalline form UPSTO
PremiumThe Fly
Cognition Therapeutics issued patent covering novel crystalline form UPSTO
6d ago
CGTX
Cognition Therapeutics issued patent extending protection for zervimesine
PremiumThe Fly
Cognition Therapeutics issued patent extending protection for zervimesine
6d ago
CGTX
Cognition Therapeutics schedules Type C meeting with FDA for trial of CT1812
PremiumThe Fly
Cognition Therapeutics schedules Type C meeting with FDA for trial of CT1812
20d ago
CGTX
Cognition Therapeutics reports Q2 EPS (4c), consensus (6c)
PremiumThe Fly
Cognition Therapeutics reports Q2 EPS (4c), consensus (6c)
2M ago
CGTX
Cognition Therapeutics gets FDA feedback on zervimesine study
PremiumThe FlyCognition Therapeutics gets FDA feedback on zervimesine study
4M ago
CGTX
Cognition Therapeutics Shareholders Elect Directors, Ratify Auditor
Premium
Company Announcements
Cognition Therapeutics Shareholders Elect Directors, Ratify Auditor
4M ago
8K
CGTX
Cognition Therapeutics gets notice of allowance from USPTO for zervimesine
Premium
The Fly
Cognition Therapeutics gets notice of allowance from USPTO for zervimesine
4M ago
CGTX
Cognition Therapeutics Advances Zervimesine Toward Phase 3 DLB Trial
PremiumCompany Announcements
Cognition Therapeutics Advances Zervimesine Toward Phase 3 DLB Trial
5M ago
8K
CGTX
Analyst Reiterates Buy on Cognition Therapeutics as FDA Clarifies Zervimesine Path; Maintains $3 Price Target
PremiumRatings
Analyst Reiterates Buy on Cognition Therapeutics as FDA Clarifies Zervimesine Path; Maintains $3 Price Target
5M ago
CGTX
Cognition Therapeutics Advances Zervimesine Toward Late-Stage DLB Trial
PremiumCompany Announcements
Cognition Therapeutics Advances Zervimesine Toward Late-Stage DLB Trial
5M ago
8K
CGTX
Cognition Therapeutics conducts zervimesine meeting with FDA
PremiumThe Fly
Cognition Therapeutics conducts zervimesine meeting with FDA
5M ago
CGTX
Ram Selvaraju Reiterates Buy on Cognition Amid Clinical Progress and Regulatory Milestones, Keeps 12-Month Price Target Unchanged at $3
PremiumRatingsRam Selvaraju Reiterates Buy on Cognition Amid Clinical Progress and Regulatory Milestones, Keeps 12-Month Price Target Unchanged at $3
5M ago
CGTX
Cognition Therapeutics reports Q1 EPS (5c), consensus (7c)
Premium
The Fly
Cognition Therapeutics reports Q1 EPS (5c), consensus (7c)
5M ago
CGTX
Cognition Therapeutics: Buy Rating Backed by Zervimesine Pivotal Path and Risk‑Adjusted Upside Across Neurodegenerative Indications
Premium
Ratings
Cognition Therapeutics: Buy Rating Backed by Zervimesine Pivotal Path and Risk‑Adjusted Upside Across Neurodegenerative Indications
7M ago
CGTX
Cognition Therapeutics Highlights 2025 Results, Zervimesine Progress
PremiumCompany Announcements
Cognition Therapeutics Highlights 2025 Results, Zervimesine Progress
7M ago
8K
CGTX
Cognition Therapeutics’ zervimesine shows eficacy in dementia trial
PremiumThe Fly
Cognition Therapeutics’ zervimesine shows eficacy in dementia trial
7M ago
CGTX
Cognition Therapeutics: FDA-Aligned Late-Stage Path for Zervimesine in DLB Psychosis and Alzheimer’s Supports Reiterated Buy Rating
PremiumRatings
Cognition Therapeutics: FDA-Aligned Late-Stage Path for Zervimesine in DLB Psychosis and Alzheimer’s Supports Reiterated Buy Rating
8M ago
CGTX
Cognition Therapeutics Advances Zervimesine for DLB Psychosis
PremiumCompany Announcements
Cognition Therapeutics Advances Zervimesine for DLB Psychosis
8M ago
8K
CGTX
Cognition Therapeutics announces plans to advance development of zervimesine
PremiumThe FlyCognition Therapeutics announces plans to advance development of zervimesine
8M ago
CGTX
Cognition Therapeutics extends duration of EAP for zervimesine
Premium
The Fly
Cognition Therapeutics extends duration of EAP for zervimesine
9M ago
CGTX
Cognition Therapeutics Advances Zervimesine Toward Phase 2b Trial
Premium
Company Announcements
Cognition Therapeutics Advances Zervimesine Toward Phase 2b Trial
9M ago
8K
CGTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >